News & Events about Cyteir Therapeutics Inc.
Business Wire
8 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today presented results from a Phase 1 dose escalation monotherapy trial with CYT-0851 in a poster titled Phase 1 Results of CYT-0851 in...
Business Wire
8 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies...
Business Wire
9 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs...
Business Wire
9 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced today that Adam Veness, Esq. has joined Cyteir as General Counsel effective today. In this role, Mr. Veness will be part of...
Business Wire
9 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a virtual R&D Day on April 26, 2022 starting at 8:30 a.m. ET. Cyteirs management will discuss the research done to...